Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Dezember 2018 08:30 ET | Quelle: Vaccinex, Inc.

Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research

ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
15. November 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting

Company Reviews Mechanism of Action, Preclinical Outcomes and Phase 1 Safety Results of VX15 (pepinemab) as Single Agent and In Combination Therapy Against Multiple Cancers ROCHESTER, N.Y., Nov. 15,...
13. November 2018 07:58 ET | Quelle: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Lead candidate pepinemab (VX15) being evaluated in three ongoing clinical trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s...
12. November 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting

Presentation and Poster Include Previously Announced Results of Cohort A of SIGNAL Trial ROCHESTER, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...
06. November 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease

ROCHESTER, N.Y., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
23. Oktober 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018

ROCHESTER, N.Y., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
02. Oktober 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

ROCHESTER, N.Y., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
27. September 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

ROCHESTER, N.Y., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
25. September 2018 08:30 ET | Quelle: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference

ROCHESTER, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
09. August 2018 09:08 ET | Quelle: Vaccinex, Inc.

Vaccinex Announces Pricing of Initial Public Offering

ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...

Vorherige Seite